insights_auto
Why is SYK up 2.03%?
Dive Deeperchevron_right
SYK:NYSE
Stryker Corp
$300.66
arrow_upward
+2.03%(+5.97) 1D
Oct 19, 2:29:07 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for SYK...
Open
$290.42
High
$301.06
Low
$290.01
Mkt. cap
115.46B
Avg. vol.
2.96M
Volume
1.62M
Dividend
1.17%
Quarterly dividend
$0.88
Ex-dividend date
Sep 30, 2026
P/E ratio
31.15
52-wk high
$392.55
52-wk low
$267.00
EPS
$9.65
Beta
0.77
Shares outstanding
383.57M
No. of employees
56K
Open
$290.42
High
$301.06
Low
$290.01
Mkt. cap
115.46B
Avg. vol.
2.96M
Volume
1.62M
Dividend
1.17%
Quarterly dividend
$0.88
Ex-dividend date
Sep 30, 2026
P/E ratio
31.15
52-wk high
$392.55
52-wk low
$267.00
EPS
$9.65
Beta
0.77
Shares outstanding
383.57M
No. of employees
56K
News stories
From web sources and news partners
MarketBeat
·
45 minutes ago
Stryker Corporation $SYK Stock: Talbot Financial LLC Increases Holdings
Yahoo Finance
·
3 hours ago
Is Stryker Corp. (SYK) Positioned for Above-Market Growth?
Zacks
·
4 hours ago
Stryker Enters Soft-Tissue Robotics With $400 Million CMR Deal
Yahoo Finance
·
5 hours ago
Stryker Enters Soft-Tissue Robotics With $400 Million CMR Deal
Profile
Stryker Corporation is an American multinational medical technologies corporation based in Portage, Michigan, United States. The company's products are used for medical surgery and neurotechnology, which include surgical equipment, patient and caregiver safety technologies, endoscopy systems, and patient handling, emergency medical equipment, and intensive care disposable products, as well as neurosurgical, neurovascular and oral and maxillofacial surgery implant products; and orthopedic surgery, which includes implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. Stryker's products are sold in over 75 countries and are used by 150 million patients annually. In 2024, 75% of the company's revenues came from the United States.
The company is ranked 195th on the Fortune 500 and 331st on the Forbes Global 2000. Wikipedia
About Stryker Corp
CEOKevin A. Lobo
Employees56K
Founded1941
HeadquartersKalamazoo, Michigan, United States
SectorMedical device
Websitestryker.com
Analyst ratings
Based on 20 analysts giving stock ratings to SYK in the past 3 months
Strong buy
Buy
18
Hold
2
Sell
0
12-month forecast
Based on 20 Wall Street analysts offering 12 month price targets for SYK in the last 3 months.
Highest
Current $300.66
$420.00 (+39.69%)
Average
$364.72 (+21.31%)
Lowest
$298.00 (-0.88%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Vik Chopra BMO Capital | Buy | Maintained | $317.00 | +5.4% | 10/12/2026 |
Caitlin Roberts Canaccord Genuity | Buy | Reiterated | $385.00 | +28.1% | 10/13/2026 |
Christopher Pasquale Barclays | Buy | Maintained | $375.00 | +24.7% | 10/13/2026 |
Ryan Zimmerman BTIG | Buy | Maintained | $316.00 | +5.1% | 10/12/2026 |
Mike Kratky Leerink Partners | Buy | Reiterated | $353.00 | +17.4% | 10/12/2026 |
Joanne Wuensch Citi | Buy | Maintained | - | - | 10/07/2026 |
Travis Steed Bank of America Securities | Buy | Maintained | $380.00 | +26.4% | 10/06/2026 |
Matt Miksic Barclays | Buy | Maintained | $375.00 | +24.7% | 10/07/2026 |
Richard Newitter Truist Financial | Hold | Maintained | $310.00 | +3.1% | 10/06/2026 |
Michael Matson Needham | Buy | Maintained | $418.00 | +39% | 10/06/2026 |
Kendall Au RBC Capital | Buy | Maintained | $420.00 | +39.7% | 10/01/2026 |
Rick Wise Stifel Nicolaus | Buy | Maintained | $330.00 | +9.8% | 09/30/2026 |
Matthew Taylor Jefferies | Buy | Maintained | $405.00 | +34.7% | 09/22/2026 |
Mathew Blackman TD Cowen | Hold | Reiterated | $298.00 | -0.9% | 09/22/2026 |
William Plovanic Canaccord Genuity | Buy | Reiterated | $385.00 | +28.1% | 09/18/2026 |
Shagun Singh Chadha RBC Capital | Buy | Reiterated | $420.00 | +39.7% | 09/16/2026 |
Larry Biegelsen Wells Fargo | Buy | Reiterated | $348.00 | +15.7% | 09/16/2026 |
Steven Lichtman William Blair | Buy | Reiterated | - | - | 09/09/2026 |
Robbie Marcus J.P. Morgan | Buy | Maintained | $350.00 | +16.4% | 08/04/2026 |
David Turkaly Citizens JMP | Buy | Maintained | $400.00 | +33% | 08/03/2026 |
Jayson Bedford Raymond James | Buy | Maintained | $370.00 | +23.1% | 07/31/2026 |
Matthew O'Brien Piper Sandler | Buy | Maintained | $390.00 | +29.7% | 07/31/2026 |
Patrick Wood UBS | Buy | Upgraded | $400.00 | +33% | 07/28/2026 |
David Toung Argus Research | Buy | Reiterated | $370.00 | +23.1% | 07/09/2026 |
Unknown Analyst Wells Fargo | Buy | Maintained | $418.00 | +39% | 07/08/2026 |
Unknown Analyst BMO Capital | Buy | Initiated | $369.00 | +22.7% | 07/09/2026 |
Vijay Kumar Evercore ISI | Buy | Maintained | $350.00 | +16.4% | 07/06/2026 |
David Roman Goldman Sachs | Hold | Maintained | $361.00 | +20.1% | 05/01/2026 |
Jeff Johnson Robert W. Baird | Buy | Maintained | $385.00 | +28.1% | 05/01/2026 |
Pito Chickering Deutsche Bank | Hold | Maintained | $315.00 | +4.8% | 05/01/2026 |
Lee Hambright Bernstein | Buy | Maintained | $410.00 | +36.4% | 05/01/2026 |
Nico Chen DBS | Buy | Maintained | $450.00 | +49.7% | 03/18/2026 |
Danielle Antalffy UBS | Hold | Reiterated | $380.00 | +26.4% | 03/17/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $465.00 | +54.7% | 03/05/2026 |
Next call in 10 days
Thu, Oct 29, 10:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $3.55
Revenue / Est. (USD)
- / 6.62B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 6.06B | 7.17B | 6.02B | 6.59B |
Cost of goods sold | 2.12B | 2.49B | 2.19B | 2.08B |
Cost of revenue | 2.12B | 2.49B | 2.19B | 2.08B |
Research and development expenses | 409.00M | 388.00M | 409.00M | 429.00M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 1.99B | 2.15B | 2.16B | 2.13B |
Operating expense | 2.58B | 2.72B | 2.75B | 2.73B |
Total operating expenses | 4.71B | 5.22B | 4.95B | 4.81B |
Operating income | 1.35B | 1.95B | 1.07B | 1.78B |
Other non operating income | -138.00M | 420.00M | 19.00M | 1.00M |
EBT including unusual items | 1.03B | 1.70B | 850.00M | 1.56B |
EBT excluding unusual items | 1.25B | 1.81B | 987.00M | 1.68B |
Income tax expense | 170.00M | 856.00M | 105.00M | 288.00M |
Effective tax rate | 16.52% | 50.21% | 12.35% | 18.41% |
Other operating expenses | - | - | - | - |
Net income | 859.00M | 849.00M | 745.00M | 1.28B |
Net profit margin | 14.18% | 11.84% | 12.38% | 19.37% |
Earnings per share | 3.19 | 4.47 | 2.60 | 3.69 |
Interest and investment income | 28.00M | 31.00M | 34.00M | 26.00M |
Interest expense | - | -607.00M | -148.00M | -141.00M |
Net interest expenses | 28.00M | -576.00M | -114.00M | -115.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 1.66B | 2.27B | 1.37B | 2.08B |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1